BioHarvest Sciences Reports Record-Breaking Q4 2025 Results, Positions Itself for Future Growth
On March 31st, 2026, BioHarvest Sciences (the company) held its quarterly conference call to discuss the company's Q4 2025 results and future prospects. During the call, Ilan Sobel, Chief Executive Officer, presented a comprehensive overview of the company's progress.
The CEO emphasized that BioHarvest Sciences is committed to "discovering, developing, manufacturing, and democratizing life-changing compounds from plants" that will positively impact human health and wellness while preserving the planet for future generations. The company has made significant strides in this direction through its patented Botanical Synthesis technology.
BioHarvest Sciences' proprietary platform allows it to produce plant-derived compounds with greater potency than those found naturally, using a non-GMO process that involves identifying and optimizing the production of critical phytonutrients from plant cells. This innovative approach enables the company to create highly soluble, bioavailable, and efficacious final materials on an industrial scale.
The CEO highlighted two distinct business units within BioHarvest Sciences: Direct-to-Consumer Products, led by the VINIA nutraceutical platform, and CDMO Services, which partners with third parties to develop novel plant-based compounds using the company's Botanical Synthesis technology. These dual growth engines provide multiple pathways for revenue growth and long-term shareholder value creation.
The Q4 2025 results were particularly impressive, with revenues reaching $9.1 million, up 25% year-over-year, and gross margins of 58%, a 100 basis-point increase compared to the same period in 2024. The company's Direct-to-Consumer Products business recorded a record number of sales orders in December 2025, generating over $3 million in sales for that month alone.
Looking ahead, the CEO expressed optimism about the company's prospects for future growth. While expecting the D2C business to achieve profitability in 2026, BioHarvest Sciences believes its CDMO Services division has the potential to accelerate meaningfully in 2026 and beyond, supported by continued investment in technology, capabilities, and commercial infrastructure.
BioHarvest Sciences' commitment to innovation, sustainability, and customer satisfaction has positioned it for long-term success. With a solid foundation in place, the company is well-equipped to drive growth and create value for its shareholders in the years to come.
